Establishment Labs (NASDAQ:ESTA – Get Free Report) had its price target cut by equities research analysts at TD Cowen from $117.00 to $95.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen‘s price objective would suggest a potential upside of 42.59% from the company’s previous close.
A number of other research firms also recently commented on ESTA. JPMorgan Chase & Co. increased their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Stifel Nicolaus set a $85.00 target price on shares of Establishment Labs and gave the company a “buy” rating in a report on Wednesday, October 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Thursday, August 13th. Finally, Needham & Company LLC boosted their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $96.11.
Check Out Our Latest Stock Analysis on ESTA
Establishment Labs Trading Up 4.4%
NASDAQ:ESTA traded up $2.82 on Monday, reaching $66.62. The company’s stock had a trading volume of 77,630 shares, compared to its average volume of 510,428. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -50.76 and a beta of 1.06. Establishment Labs has a 12-month low of $47.00 and a 12-month high of $97.59. The stock has a 50 day moving average price of $67.87 and a 200 day moving average price of $74.62. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11.
Establishment Labs (NASDAQ:ESTA – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The firm had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. During the same quarter last year, the company earned ($0.57) earnings per share. The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. On average, equities analysts anticipate that Establishment Labs will post -1.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Establishment Labs
Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Establishment Labs during the 2nd quarter worth approximately $135,752,000. William Blair Investment Management LLC purchased a new position in shares of Establishment Labs during the 2nd quarter valued at approximately $61,273,000. Bank of America Corp DE purchased a new position in shares of Establishment Labs during the 2nd quarter valued at approximately $52,176,000. Rice Hall James & Associates LLC acquired a new stake in shares of Establishment Labs during the second quarter worth approximately $48,134,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Establishment Labs during the second quarter worth approximately $28,817,572. Institutional investors and hedge funds own 72.91% of the company’s stock.
About Establishment Labs
Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.
Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.
Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.
Featured Articles
- Five stocks we like better than Establishment Labs
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
- Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
- Valero’s Windfall Quarter Meets Washington’s Push for Cheaper Diesel
- 4 Small-Cap Stocks With Paths to Recovery After the Fed’s September Rate Hike
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
